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Hemoglobin-based oxygen carrier HBOC-201
provides higher and faster increase in oxygen
tension in skeletal muscle of anemic dogs than do
stored red blood cells
Th. Standl, MD, M. Freitag, MD, M. A. Burmeister, MD, E. P. Horn, MD, S. Wilhelm, MD, and
J. Schulte am Esch, MD, Hamburg, Germany
Background: Increasing need for and potential shortage of blood products have intensified the search for alternative
oxygen carriers. A solution to this problem could be use of the bovine hemoglobin-based oxygen carrier HBOC-201.
While hemodynamic reactions to cell-free hemoglobin have been studied, little knowledge exists about tissue oxygenation
properties of hemoglobin solutions, especially in comparison with red blood cells (RBCs).
Study design and methods: Tissue oxygenation in skeletal muscle of 12 anesthetized dogs was examined after decrease of
hemoglobin concentrations by means of hemodilution to hematocrit 10% and subsequent transfusion with either
HBOC-201 or autologous banked RBCs. In addition to hemodynamic parameters, blood gas concentrations and oxygen
content in arterial and muscular venous blood, tissue oxygen tension (tPO2) were measured in the gastrocnemius muscle
with a polarographic needle probe.
Results: Hemodilution increased muscular blood flow and oxygen extraction and decreased tPO2. Transfusion decreased
muscular oxygen extraction in the RBC group but not in the HBOC-201 group (P < .01). The 10th percentile of tPO2
increased by 400% after the first dose of HBOC-201 (P < .001 vs posthemodilution) but only by 33% after equivalent
RBC transfusion (P < .01 vs HBOC-201). Increases in the 50th (120%, P < .05) and 90th (31%) percentiles and all
percentiles of tPO2 after the second and third HBOC-201 dose were less pronounced but higher than in the RBC group.
Conclusion: Compared with RBC transfusion, infusion of low doses of HBOC-201 maintain enhanced oxygen extraction
after extended hemodilution and provide faster and higher increase in muscular tissue PO2. (J Vasc Surg 2003;37:
859-65.)
A remarkable shortage of allogeneic blood may occur in
the industrialized countries within the next two or three
decades.1 Against this background and because of the
remaining risks associated with the transfusion of blood
components,2-5 demand for artificial oxygen carriers could
increase.6,7 Modern cell-free hemoglobin-based oxygen
carriers (HBOCs) have been used to overcome earlier
problems related to impurities and red blood cell (RBC)
debris by ultrapurification.8,9 Clinical studies have docu-
mented the safety and tolerability of the ultrapurified poly-
merized bovine hemoglobin HBOC-201 in volunteers and
patients.10,11 Furthermore, there is evidence that HBOC-
201 may diminish or eliminate the need for banked blood
in patients undergoing major vascular surgery.12,13 Indeed,
South African authorities, faced with significant viral safety
problems in the blood supply, in 2000 approved HBOC-
201 for treatment of acute anemia. A unique feature of
HBOC-201, room temperature stability for more than 2
years, offers the opportunity for widespread use of this
material in clinical settings. Unlike unmodified human
cell-free hemoglobin, which has a high oxygen affinity
(p50  13 mm Hg), bovine hemoglobin has a low oxygen
affinity (p50  36 mm Hg), which is regulated by plasma
chloride concentration rather than 2,3-diphosphoglycer-
ate.14 Stable hemodynamic conditions during resuscitation
from hemorrhagic shock15,16 or during nearly complete
blood exchange with HBOC-201 have been demonstrat-
ed,17,18 as has increased tissue oxygen tension (tPO2) dur-
ing blood exchange17 and in comparison with transfusion
of different RBCs.19 In a model of artificial arterial stenosis,
HBOC-201 restored substantially decreased poststenotic
tissue oxygen tension in skeletal muscle by increasing oxy-
gen extraction,20 suggesting that this material might have
beneficial indications in vascular surgery, acute myocardial
infarction, cerebrovascular accident (stroke), and chronic
and acute vascular diseases. We investigated the clinically
relevant question of equivalence or difference between
cell-free and cellular oxygen carriers with respect to their
tissue oxygenation potential.
METHODS
The study included 12 foxhounds and was approved by
the local Animal Care Committee. On the day of the
experiment the dogs (mean age, 20 5 mo; mean weight,
29 4 kg) were anesthetized with intravenous infusions of
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fentanyl at 0.025 mg/kg/h, midazolam at 0.4 mg/kg/h,
and vecuronium at 0.2 mg/kg/h, and mechanical ventila-
tion was provided with 30% oxygen in air. Minute ventila-
tion was adjusted to maintain end-expiratory partial pres-
sure of carbon dioxide (PCO2) constant (36-40 mm Hg;
Normocap; Datex, Helsinki, Finland).
Measurements. An arterial line was inserted into the
aorta to measure mean arterial pressure (MAP) and for
blood sampling to measure arterial blood gas levels and
arterial oxygen content (CaO2). A 6F minitip catheter (Sen-
sodyn FPO; B. Braun, Melsungen, Germany) was inserted
into the left ventricle for continuous measurement of left
ventricular end-diastolic pressure (LVEDP) and maintain-
ance of intravascular volume over time (T). The left hind
limb of the animals was prepared for measurements of the
left gastrocnemius muscle. An electromagnetic flow probe
(Cliniflow FK 701 D; Carolina Medical Electronics, Wil-
mington, NC) was placed at the left popliteal artery, which
is the main vessel in the gastrocnemius muscle for measur-
ing mean arterial blood flow to the muscle. A small catheter
was inserted into the left popliteal vein for sampling venous
blood from the left gastrocnemius muscle. Peripheral ve-
nous blood gases, venous lactate concentrations (lactate-
specific test kit; Boehringer, Mannheim, Germany), and
venous oxygen content (CvpO2)were measured. Oxygen
concentrations were measured with an oxygen-specific fuel
cell (Lex-O2-Con, Lexington Instruments, Waltham,
Mass).
tPO2 was measured in the left gastrocnemius muscle
with a microprocessor-controlled fast responding polaro-
graphic needle probe with 12.5 mm diameter (Helzel
Medical Systems, Kaltenkirchen, Germany), yielding 200
single tPO2 values within 5 minutes in a 2 to 3 cm
3 conical
muscular tissue area. At each measurement 1200 single
tPO2 values were collected.
Plasma viscosity was measured with a viscosimeter
(Rheomat; Fresenius, Bad Homburg, Germany) and col-
loid osmotic pressure (COP) with an oncometer (BMT
851; Thomae, Biberach, Germany).
Calculated variables. Variables were calculated with
the following equations: muscular arteriovenous oxygen
difference, avDO2m  CaO2  CvpO2; muscular oxygen
delivery, DO2m  Flow  CaO2; muscular oxygen con-
sumption, VO2m Flow avDO2m; and muscular oxygen
extraction ratio, ERO2m  VO2m  DO2m
1.
Study protocol. Because previous experiments dem-
onstrated that extreme isovolemic hemodilution decreases
muscular tPO2 significantly to less than 50% of baseline,
17
LVEDP-controlled hemodilution with Ringer solution was
performed until Hct 10% was reached. The removed blood
volume was replaced with a fourfold volume of Ringer
solution, and control of Hct values was performed repeti-
tively.
When Hct 10% was reached, the second measurement
was performed after stabilization (T1) and before animals
were infused with either HBOC-201 or canine RBCs, to
obtain stepwise augmentation of total arterial hemoglobin
concentration of approximately 1 g/dL (T2), 2 g/dL (T3),
and 3 g/dL (T4).
In group 1, six animals received HBOC-201 (Biopure,
Cambridge, Mass)17 with a mean hemoglobin concentra-
tion of 13  1 g/dL. In group 2, six dogs received
3-week-old banked autologous RBCs, which were stored at
4° C in 200 mL PAGGS-mannitol additive solution.
Statistics. Data are reported as mean  SEM unless
stated otherwise. Skeletal muscle tPO2 values are expressed
as median and plotted as 10th, 50th, and 90th percentiles.
All single 1200 tPO2 values were tested with the Mann
Whitney U test. For all other parameters, differences within
groups were tested with one-way analysis of variance and
post hoc comparison with the paired Student t test. Differ-
ences between groups were tested with the unpaired Stu-
dent t test. The slope ratio assay method was used to
calculate estimates of relative potency between groups.
Relative potency was estimated as the ratio of two slopes
(HBOC-201/reference  RBCs) taken from the multiple
linear regression of the posthemodilution time points.
Ninety-five percent confidence limits around relative po-
tency were calculated with the Fieller theorem. All differ-
ences were considered significant at P  .05.
The authors conceived and designed the study; had full
access to all of the data from the study; and take responsi-
bility for integrity of the data, accuracy of data analysis and
interpretation, and for writing the manuscript and submit-
ting it for publication.
RESULTS
Hemodynamic and rheologic parameters are given in
Table I. Arterial and popliteal venous blood gas parameters,
and core and skeletal muscle temperatures are shown in
Table II.
Oxygen transport parameters. The target posthe-
modilution Hct of 10% 1% was reached in both groups
(P  .001) and remained unchanged during infusion of
HBOC-201, but it was continuously increased during RBC
transfusion in group 2 (P  .001 vs group 1; Table III).
Total arterial hemoglobin concentration (cellular plus
plasma) increased in both groups. Arterial and popliteal
venous oxygen content was decreased during hemodilution
(P  .001) and reversibly increased during application of
the respective oxygen carrier in both groups, but popliteal
venous oxygen content was lower during infusion of
HBOC-201 when compared with group 2 during RBC
transfusion (P  .01). Muscle oxygen delivery was de-
creased in both groups compared with baseline (P  .05),
and it was higher for the RBC transfusion group compared
with the HBOC-201 group at the end of infusion. Oxygen
consumption was higher after the second and third infu-
sions of HBOC-201 in comparison with group 2 (P .05).
The ERO2 was increased after hemodilution in both groups
(P  .05; Fig 1). In the RBC group ERO2m returned to
baseline during transfusion, but it remained elevated dur-
ing infusion of HBOC-201 (P  .01) and was higher in
group 1 than in group 2 (P  .01 vs baseline).
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Skeletal muscle oxygen tension. In both groups a
significant decrease in muscular tPO2 values was seen after
hemodilution to Hct 10% (P  .001; Fig 2). The first
hemoglobin augmentation (T2) provided a steep increase
of all tPO2 percentiles in the HBOC-201 group, but it was
more pronounced for the 10th percentile, which showed an
increase of 400% compared with posthemodilution mea-
surements (P  .001, T2 vs T1; Fig 2). The respective
increase in the 50th percentile was 120% (P  .001, T2 vs
T1), and in the 90th percentile it was 31% (P  .05, T2 vs
T1) compared with posthemodilution values.
The second hemoglobin augmentation with HBOC-
201 (T3) continued to increase at all tPO2 percentiles, but
the enhancement was not as high as after the first applica-
tion. Again, the highest increase noted was for the 10th
percentile (525%) compared with posthemodilution values
(P  .001, T3 vs T1). For the 50th percentile the increase
was 186% (P .001, T3 vs T1), and for the 90th percentile
it was 64% (P  .05, T3 vs T1).
The third infusion of HBOC-201 (T4) provided addi-
tional but less pronounced increase at all percentiles when
compared with the first two infusions. The greatest en-
hancement was again registered for the 10th percentile
(625% over posthemodilution values; P .001, T4 vs T1).
The respective increase for the 50th percentile was 253%
(P  .001, T4 vs T1), and for the 90th percentile it was
100% (P  .001, T4 vs T1).
In group 2, RBC transfusion provided a less accentu-
ated increase in tPO2 percentiles compared with HBOC-
201 (Fig 2). The 10th percentile increased by 33% after the
first transfusion (T2), by 50% after the second transfusion
(T3), and by 180% after the third transfusion (P .05, T4
Table I. Hemodynamic and rheologic parameters before and after hemodilution and during decrease and increase in
global hemoglobin concentration with HBOC-201 or RBCs
MAP
(mm Hg)
LVEDP
(mm Hg)
Flow
(mL/min)
COP
(mm Hg) Vis (cp)
V.p.Lactate
(mg/dL)
HBOC-201
Baseline 149  16* 14  2 50  10 15.8  0.7 1.28  0.03 12.5  3.2
Time 1 105  5† 13  2 123  19† 12.4  0.5† 1.18  0.02† 8.7  0.5
Time 2 112  7 10  2 114  18† 11.1  0.5† 1.17  0.01† 9.6  0.6
Time 3 110  8 9  2† 112  16† 10.8  0.5† 1.19  0.01† 9.9  0.8
Time 4 110  7 9  2† 100  18† 10.9  0.5† 1.24  0.01* 9.9  0.8
RBC
Baseline 118  7 11  1 62  9 14.3  1.8 1.26  0.03 11.1  4.6
Time 1 98  8 10  2 149  25† 12.4  0.8† 1.14  0.03† 8.2  1.0
Time 2 103  7 8  2 121  15† 11.5  0.6† 1.16  0.02† 8.6  0.5
Time 3 104  8 8  2 110  16† 10.4  0.6† 1.17  0.03† 9.6  0.5
Time 4 107  8 10  2 112  16† 9.2  0.9† 1.17  0.03† 9.6  0.5
Values are expressed as mean  SEM.
MAP, Mean arterial pressure; LVEDP, left ventricular end-diastolic pressure; Flow, popliteal artery blood flow; COP, colloid oncotic pressure; Vis, plasma
viscosity; V.p.Lactate, popliteal venous lactate concentration.
*P  .05 compared with RBC; †P  .05 compared with baseline.
Table II. Arterial and popliteal vein blood gas level and temperature before and after hemodilution and during decrease
and increase in global hemoglobin concentration with HBOC-201 or RBCs
PaO2
(mm Hg) Arterial pH
Arterial base excess
(mmol/L)
V.p.PO2
(mm Hg) V.p.pH
V.p.BE
(mmol/L)
Core temp
(° C)
Muscle temp
(° C)
HBOC-201
Baseline 137  4 7.39  0.02 1.5  0.9* 52  4 7.35  0.02 0.7  0.7 36.2  0.5 33.4  0.7
Time 1 135  7 7.24  0.01† 8.8  0.4*† 46  3 7.18  0.02† 9.9  0.4† 37.0  0.3 33.7  0.5
Time 2 139  6 7.27  0.01† 8.4  0.2† 43  5 7.18  0.01*† 9.3  0.4† 36.8  0.3 33.8  0.5
Time 3 139  4 7.26  0.01*† 8.5  0.3*† 51  4 7.18  0.01† 9.5  0.5† 37.0  0.3 33.9  0.5
Time 4 136  11 7.24  0.01† 9.2  0.3† 57  5 7.19  0.01† 8.6  1.1*† 37.1  0.3 34.1  0.4
RBC
Baseline 137  5 7.36  0.02 3.8  0.5 58  2 7.31  0.01 3.1  0.6 36.9  0.4 34.4  0.5
Time 1 135  8 7.23  0.01† 10.1  0.4† 50  3 7.16  0.01† 10.5  0.3† 37.6  0.5 34.9  0.6
Time 2 136  5 7.26  0.04† 9.4  0.4† 52  8 7.16  0.01† 10.4  0.4† 37.6  0.4 34.7  0.6
Time 3 141  6 7.23  0.01† 10.1  0.6† 65  4 7.17  0.01† 10.6  0.3† 37.2  0.4 34.5  0.5
Time 4 145  7 7.24  0.01† 10.3  0.8† 63  3 7.18  0.01† 10.9  0.5† 37.3  0.4 34.3  0.4
Values are expressed as mean  SEM.
V.p.PO2, Popliteal vein partial pressure of oxygen; V.p.pH, popliteal vein pH; V.p.BE, popliteal vein base excess; Core temp, cava superior; Muscle temp, skeletal
muscle temperature (left gastrocnemius muscle).
*P  .05 compared with RBC.
†P  .05 compared with baseline.
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vs T1) compared with the posthemodilution measurement
(T1), and it reached baseline values only after the second
RBC transfusion (Fig 2).
The 50th percentile increased by 30%, 50%, and 105%
(P .001, T4 vs T1) over posthemodilution measurements
after the respective transfusions, and it reached baseline
values between transfusions 2 and 3.
The 90th percentile showed similar increases of 45%,
65%, and 84% (P .001, T4 vs T1) over posthemodilution
values. However, baseline values could not be restored even
after the third RBC transfusion.
Differences in muscular tPO2 enhancement between
the two treatment groups are demonstrated in Figure 2 by
the different slopes of predicted tPO2 values. The ratio of
the respective slopes at the respective percentiles provides
the relative potency of HBOC-201 in comparison with
banked RBCs. These results are given in Table 4 and show
a relative potency of HBOC-201 in the range of 2.3 to 3.0
compared with RBC. Nonlinearity of the 10th percentile
(Table 4) means that the response of the first treatment
with HBOC-201 may be greater than the response of the
last treatment.
DISCUSSION
Because of limited clinical experience with HBOC-
201,11,12 experimental data that enable comparative assess-
ment of the efficacy of HBOC-201 and commonly trans-
fused RBCs could be helpful in terms of dosing and
indications for clinical use of HBOC-201.
Fig 1. Changes in muscular oxygen extraction ratio (ERO2) during decrease and increase in global hemoglobin
concentration with HBOC-201 or RBCs. Values are expressed as mean  SEM. *P  .05; **P  .01; ***P  .001
compared with baseline; #P  .05; ##P  .01 compared with RBC group.
Table III. Muscular oxygen transport parameters before and after hemodilution and during decrease and increase in
global hemoglobin concentration with HBOC-201 or RBCs
Hct (Vol%) Hb (g/dL)
CaO2
(mL/dL)
CvpO2
(mL/dL)
avDO2m
(mL/dL)
DO2m
(mL/min)
VO2m
(mL/min)
HBOC-201
Baseline 48.0  1.6 15.9  0.6 20.8  1.0 15.9  1.9 4.9  1.1 10.1  1.7 2.6  0.9
Time 1 9.3  0.4† 2.8  0.2† 4.2  0.3† 2.4  0.3† 1.8  0.5† 5.1  0.9† 2.0  0.3
Time 2 9.4  0.6*† 3.5  0.3† 4.9  0.6† 2.4  0.3*† 2.5  0.6 5.1  0.6† 2.4  0.3
Time 3 10.0  1.1*† 4.4  0.3† 5.5  0.6† 2.6  0.5*† 2.9  0.5* 6.0  0.8† 3.0  0.2*
Time 4 10.3  1.5*† 5.7  0.5† 6.9  0.6*† 3.2  0.6*† 3.7  0.8* 6.7  0.9*† 3.5  0.7*
RBC
Baseline 44.5  2.0 14.5  0.6 19.3  0.8 15.6  0.6 3.7  0.5 11.7  1.5 2.2  0.3
Time 1 9.5  0.3† 2.8  0.2† 4.1  0.3† 2.7  0.2† 1.4  0.1† 6.2  1.0† 2.0  0.2
Time 2 12.8  0.5† 4.0  0.3† 5.6  0.4† 4.2  0.3† 1.4  0.2† 7.0  1.2† 1.7  0.3
Time 3 16.3  0.7† 5.2  0.3† 7.1  0.4† 5.6  0.3† 1.5  0.3† 7.8  1.2† 1.5  0.3
Time 4 20.2  1.0† 6.4  0.3† 8.7  0.4† 7.2  0.4† 1.5  0.2† 10.0  1.8 1.7  0.3
Values are expressed as mean  SEM.
Hct, Hematocrit; Hb, total hemoglobin concentration; CaO2, arterial oxygen content; CvpO2, popliteal venous oxygen content; avDO2m, muscular
arteriovenous oxygen difference; DO2m, muscular oxygen delivery; VO2m, muscular oxygen consumption.
*P  .05 compared with RBC.
†P  .05 compared with baseline.
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For this reason, we investigated tissue oxygenation
properties during infusion with HBOC-201 compared
with transfusion of banked RBCs after extended isovolemic
hemodilution in a model of an in vivo skeletal muscle. This
situation is common in the operating room when there is
major intraoperative bleeding, eg, during vascular surgery.
To decrease muscular tPO2 to an acceptable level, we
performed LVEDP-controlled isovolemic hemodilution,
Fig 2. Observed and predicted values (dotted lines) of skeletal muscle tPO2 at the 10th, 50th , and 90th percentiles
during decrease and increase in global hemoglobin concentration with HBOC-201 or RBCs. *P .05; **P .01; ***
P  .001 compared with baseline; # P  .05; ## P  .01 compared with RBC group; P  .05;  P  .01; 
P  .001 compared with T1.
Table IV. Summary of slope ratio assay method for HBOC-201 and RBCs
tPO2
Slopes (P)
Relative potency
HBOC-201/
RBC
P
HBOC-201 RBC
Heterogeneity
of intercepts Nonlinearity
10th percentile 9.2 (.00) 3.0 (.00) 3.03 0.64 .04
50th percentile 14.5 (.00) 6.2 (.00) 2.34 0.76 .25
90th percentile 15.1 (.00) 5.8 (.00) 2.59 0.72 .47
Note: Statistically significant P values (  .05) from testing for heterogeneity of intercepts or nonlinearity and slopes that are significantly different from zero
(  .05) are in bold type.
JOURNAL OF VASCULAR SURGERY
Volume 37, Number 4 Standl et al 863
inasmuch as tPO2 is significantly decreased by reducing Hct
to 10%.17,19,21
Hemodynamics and oxygen transport parameters.
Our data show comparable hemodynamic changes during
isovolemic hemodilution in both groups. Acidosis was also
seen in both groups after initiating hemodilution, and it
continued throughout the study, although hemodynamic
and temperature stability could be achieved. Considering
the observed stable muscular venous lactate concentrations,
this metabolic acidosis can be attributed to loss of buffers,
eg, bicarbonate, from continuous blood exchange with
bicarbonate-free Ringer solution and to increased diuresis
during hemodilution rather than anemia-related hypoxia.
Reduction of RBCs leading to lower blood viscosity
causes at least partial increase in blood flow, which might be
necessary to maintain oxygen delivery. Oxygen delivery
decreased and oxygen consumption was constant after ex-
tended hemodilution. Despite increased muscle oxygen
extraction in both groups, the increase in blood flow to the
muscular compartment alone could not compensate for the
reduced oxygen delivery and resulted in significantly de-
creased muscular tPO2 values at the end of hemodilution.
When the hemodiluted animals were given RBC transfu-
sions, ERO2m decreased toward baseline values. In con-
trast, in the HBOC-201 group, ERO2m remained higher
compared with baseline measurements and with the RBC
group. This higher ERO2m was paralleled by increased tPO2
values in the HBOC-201 group. The sustained higher
ERO2m was not caused by decreased flow due to vasocon-
striction after HBOC-201 infusion, because the flow and
DO2m did not differ between groups over time and the
muscle was in steady state (temperature and venous lactate
concentration constant, muscle paralysis by relaxation).
There are several explanations for the enhanced oxygen
extraction in the HBOC-201 group. First, HBOC-201 has
a low oxygen affinity compared with human or canine RBC
hemoglobin, which facilitates oxygen off-loading to the
tissues.14 In addition, HBOC-201 increases the oxygen
off-load from remaining RBCs. In an in vitro model with an
artificial capillary, HBOC-201, when mixed with RBCs,
increased oxygen release from RBCs compared with RBC
oxygen release alone.22
The high ERO2 with HBOC-201 is therefore neither
dependent on nor caused by reduced oxygen delivery,
which has been noted in animal experiments and clinical
studies after application of different cell-free hemoglobin
solutions.23,24 In some clinical trials with cell-free hemo-
globin, systemic vasoconstriction, possibly due to nitric
oxide scavenging, was associated with increased systemic
vascular resistance and mean arterial pressure and with
consecutive decrease in cardiac output. Because of the low
dose of cell-free hemoglobin administered in the current
study, the small increase in oxygen content did not com-
pensate for the decrease in cardiac output, resulting in a
demonstrated reduction in calculated oxygen delivery.
However, oxygen consumption was well maintained and
was associated with increased ERO2. Preclinical animal
studies have shown unaffected or even improved organ
perfusion and microcirculatory blood flow in the presence
of cell-free hemoglobin solutions, although systemic vascu-
lar resistance and mean arterial pressure were
increased.25,26 However, colloid osmotic pressure and
plasma viscosity were finally higher in the HBOC-201
group because of the colloidal properties of the hemoglo-
bin solution. Thus it remains unclear whether there was
also a contribution from the changed colloid osmotic pres-
sure and the blood or plasma viscosity to changes in mus-
cular tPO2.
Tissue oxygenation and relative potency of HBOC-
201. The exact mathematical calculation of the relative
oxygenation potential of both acellular and cellular oxygen
carriers means that smaller doses of HBOC-201 will pro-
vide the same oxygenation effect in comparison with
3-week-old stored RBCs, which may suffer from aging,
storage, and preparation processes, although rejuvenation
occurs in banked RBCs within the first hours after transfu-
sion.
The result that tissue areas with significantly reduced
tPO2 profit most by infusion of acellular hemoglobin might
be explained in that HBOC-201, in contrast to RBCs, is
not prioritized on the microcirculatory site. This makes an
increase in tPO2 faster and more pronounced in poorly
oxygenated tissues, represented by the 10th percentile of
the tPO2 values, which are less supplied by RBCs at this
time. However, the lower increase in tPO2 in the 50th and
90th percentiles indicates that HBOC-201 does not have
the same high oxygenation potential for tPO2 enhancement
in areas where high oxygen off-loading and tissue oxygen-
ation are already provided by high RBC perfusion and
oxygen off-loading, thus possibly preventing adequately
supplied tissues from hyperoxygenation.
Another aspect of our results is the declining effect of
HBOC-201 increasing muscular tissue oxygenation to the
same extent by further application of the drug. This makes
a certain first-pass effect of HBOC-201 likely, in which all
tissues are reached by HBOC-201 with the first plasma
stream and probably the tissues with low tPO2 extract the
highest amount of oxygen and are approximately saturated
when the next dose of HBOC-201 is given. This effect
equilibrates the distribution between the oxygen in plasma
and tissue and may also prevent the tissues from becoming
overloaded with oxygen.
The early first-pass effect of a low dose of HBOC-201
offers opportunities in experimental and clinical settings
such as profound acute anemia or ischemia and reperfusion.
These indications, where fast increase in tissue oxygenation
is crucial, include tissue hypoxia due to arterial stenosis,
myocardial infarction, stroke, and arterial clamping during
vascular surgery.
In conclusion, HBOC-201 has a 2.3-fold to 3-fold
higher first- pass oxygenation potential compared with
banked RBCs, providing faster and higher increase in tPO2
in muscular tissue with reduced oxygenation after acute
anemia.
Limitations of the study. We did not use an isolated
muscle model, because we wanted to control clinically
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relevant hemodynamic parameters such as blood flow and
to maintain isovolemic conditions. Since the popliteal ar-
tery and vein are the main vessels of the gastrocnemius
muscle, the values obtained should reflect representative
data for this muscle but certainly not for other organs or for
an entire organism. However, although less important than
vital organs, the skeletal muscle mass represents a major
part of mammal and human tissue, is easily accessible, and
can be used to measure tPO2 even in patients, as shown by
Boekstegers et al27 in patients undergoing cardiac surgery.
Under steady-state conditions (temperature, paralysis),
muscular tPO2 measurements are highly reproduc-
ible.17,19,21
Unlike in group 2, autologous blood was not available
for animals receiving HBOC-201. As a consequence, these
animals demonstrated a trend to lower baseline Hct com-
pared with the RBC group. However this difference was
not significant. The more important Hct for the evaluation
of oxygenation potency is the posthemodilution value
(T2), which figures as a second baseline value before initi-
ation of therapy with the respective oxygen carrier. These
Hct values were nearly identical: 9.3 0.4 for the HBOC-
201 group versus 9.5  0.3 for the RBC group.
We thank Biopure Corp. for providing HBOC-201;
Edward Jacobs, MD, for intensive discussion of our results;
and Susan M. Severance, MPH, biostatistician, for help
with statistical testing of the data.
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